187 related articles for article (PubMed ID: 35332071)
1. Drug-induced interstitial lung disease.
Spagnolo P; Bonniaud P; Rossi G; Sverzellati N; Cottin V
Eur Respir J; 2022 Oct; 60(4):. PubMed ID: 35332071
[TBL] [Abstract][Full Text] [Related]
2. Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis.
Atzeni F; Boiardi L; Sallì S; Benucci M; Sarzi-Puttini P
Expert Rev Clin Immunol; 2013 Jul; 9(7):649-57. PubMed ID: 23899235
[TBL] [Abstract][Full Text] [Related]
3. Drug-Induced Interstitial Lung Diseases.
Ng N; Padilla ML; Camus P
Immunol Allergy Clin North Am; 2023 May; 43(2):341-357. PubMed ID: 37055092
[TBL] [Abstract][Full Text] [Related]
4. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.
Roubille C; Haraoui B
Semin Arthritis Rheum; 2014 Apr; 43(5):613-26. PubMed ID: 24231065
[TBL] [Abstract][Full Text] [Related]
5. [Interstitial lung disease in systemic sclerosis].
Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
Rev Mal Respir; 2007 Oct; 24(8):1035-46. PubMed ID: 18033190
[TBL] [Abstract][Full Text] [Related]
6. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.
Perez-Alvarez R; Perez-de-Lis M; Diaz-Lagares C; Pego-Reigosa JM; Retamozo S; Bove A; Brito-Zeron P; Bosch X; Ramos-Casals M
Semin Arthritis Rheum; 2011 Oct; 41(2):256-64. PubMed ID: 21277618
[TBL] [Abstract][Full Text] [Related]
7. The risk of interstitial lung disease during biological treatment in Japanese patients with psoriasis.
Matsumoto Y; Abe N; Tobita R; Kawakami H; Nakayama H; Setoguchi Y; Tsuboi R; Okubo Y
Clin Exp Dermatol; 2020 Oct; 45(7):853-858. PubMed ID: 32356612
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
He C; Li W; Xie Q; Yin G
Front Immunol; 2021; 12():820163. PubMed ID: 35116041
[TBL] [Abstract][Full Text] [Related]
9. Non-infectious pulmonary toxicity of rituximab: a systematic review.
Hadjinicolaou AV; Nisar MK; Parfrey H; Chilvers ER; Ostör AJ
Rheumatology (Oxford); 2012 Apr; 51(4):653-62. PubMed ID: 22157468
[TBL] [Abstract][Full Text] [Related]
10. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management.
Dai Y; Wang W; Yu Y; Hu S
Clin Rheumatol; 2021 Apr; 40(4):1211-1220. PubMed ID: 32794076
[TBL] [Abstract][Full Text] [Related]
12. Interstitial lung disease in systemic sclerosis.
Bussone G; Mouthon L
Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
[TBL] [Abstract][Full Text] [Related]
13. A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease.
Li L; Liu R; Zhang Y; Zhou J; Li Y; Xu Y; Gao S; Zheng Y
Clin Rheumatol; 2020 May; 39(5):1457-1470. PubMed ID: 31858341
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in rheumatoid arthritis-associated interstitial lung disease.
Juge PA; Crestani B; Dieudé P
Curr Opin Pulm Med; 2020 Sep; 26(5):477-486. PubMed ID: 32701675
[TBL] [Abstract][Full Text] [Related]
15. Interstitial lung disease induced by drugs and radiation.
Camus P; Fanton A; Bonniaud P; Camus C; Foucher P
Respiration; 2004; 71(4):301-26. PubMed ID: 15316202
[TBL] [Abstract][Full Text] [Related]
16. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer.
Nakanishi Y; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Tsutani Y; Iwamoto H; Fujitaka K; Miyata Y; Hamada H; Okada M; Hattori N
Respir Investig; 2019 Sep; 57(5):451-459. PubMed ID: 31248832
[TBL] [Abstract][Full Text] [Related]
17. Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis.
Kurata I; Tsuboi H; Terasaki M; Shimizu M; Toko H; Honda F; Ohyama A; Yagishita M; Osada A; Ebe H; Kawaguchi H; Takahashi H; Hagiwara S; Asashima H; Kondo Y; Matsumoto I; Sumida T
Intern Med; 2019 Jun; 58(12):1703-1712. PubMed ID: 30799358
[TBL] [Abstract][Full Text] [Related]
18. Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis.
Nakashita T; Ando K; Kaneko N; Takahashi K; Motojima S
BMJ Open; 2014 Aug; 4(8):e005615. PubMed ID: 25125479
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulation in Autoimmune Interstitial Lung Disease.
Seeliger B; Prasse A
Respiration; 2020; 99(10):819-829. PubMed ID: 33271551
[TBL] [Abstract][Full Text] [Related]
20. Management issues in rheumatoid arthritis-associated interstitial lung disease.
England BR; Hershberger D
Curr Opin Rheumatol; 2020 May; 32(3):255-263. PubMed ID: 32141954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
